Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Alexis

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Dermatology and Therapy|March 17, 2022
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE StudyAndrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
The British Journal of Dermatology|January 10, 2025
Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colourChristopher Hartford, Andrew Alexis, Zhixiao Wang, et al.
Dermatology and Therapy|June 30, 2025
Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial MelasmaThierry Passeron, Delphine Kerob, Guénaëlle Le Dantec, et al.
Dermatology and Therapy|July 22, 2023
Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Vivian Y Shi, Andrew Alexis, et al.
Dermatology and Therapy|December 10, 2025
Paving the Way to Healthcare Equity: A Comprehensive Review of Care Gaps and Emerging Initiatives in DermatologyAndrew Alexis, Raj Chovatiya, Susan Taylor, et al.
The Journal of Allergy and Clinical Immunology|August 27, 2019
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritusJonathan I Silverberg, Andreas Pinter, Grazyna Pulka, et al.
JAAD International|November 24, 2021
Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panelAlison Layton, Andrew Alexis, Hilary Baldwin, et al.
JAAD International|November 24, 2021
The Personalised Acne Care Pathway-Recommendations to guide longitudinal management from the Personalising Acne: Consensus of ExpertsJerry Tan, Andrew Alexis, Hilary Baldwin, et al.
JAAD International|November 24, 2021
Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panelJerry Tan, Andrew Alexis, Hilary Baldwin, et al.
Dermatology Online Journal|October 31, 2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panelAngela Rosenberg, Danny Zakria, Lauren DeBusk, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Dermatology and Therapy|March 17, 2022
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE StudyAndrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
The British Journal of Dermatology|January 10, 2025
Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colourChristopher Hartford, Andrew Alexis, Zhixiao Wang, et al.
Dermatology and Therapy|June 30, 2025
Efficacy and Tolerability of a New Facial 2-Mercaptonicotinoyl Glycine-Containing Depigmenting Serum Versus Hydroquinone 4% over 3-Month Treatment of Facial MelasmaThierry Passeron, Delphine Kerob, Guénaëlle Le Dantec, et al.
Dermatology and Therapy|July 22, 2023
Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Vivian Y Shi, Andrew Alexis, et al.
Dermatology and Therapy|December 10, 2025
Paving the Way to Healthcare Equity: A Comprehensive Review of Care Gaps and Emerging Initiatives in DermatologyAndrew Alexis, Raj Chovatiya, Susan Taylor, et al.
The Journal of Allergy and Clinical Immunology|August 27, 2019
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritusJonathan I Silverberg, Andreas Pinter, Grazyna Pulka, et al.
JAAD International|November 24, 2021
Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panelAlison Layton, Andrew Alexis, Hilary Baldwin, et al.
JAAD International|November 24, 2021
The Personalised Acne Care Pathway-Recommendations to guide longitudinal management from the Personalising Acne: Consensus of ExpertsJerry Tan, Andrew Alexis, Hilary Baldwin, et al.
JAAD International|November 24, 2021
Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panelJerry Tan, Andrew Alexis, Hilary Baldwin, et al.
Dermatology Online Journal|October 31, 2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panelAngela Rosenberg, Danny Zakria, Lauren DeBusk, et al.
Pageof 8